HUBEI HONGYUAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

Hubei Hongyuan Pharmaceutical Technology Co., Ltd.

301246

CNE100005ZB9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
13.49 ^CNY	+0.67%		-0.52%	-48.08%

Jul. 03	Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Announces 2023 Final Profit Distribution of A Shares, Payable on 09 July 2024	CI
Jul. 03	Tranche Update on Hubei Hongyuan Pharmaceutical Technology Co., Ltd.'s Equity Buyback Plan announced on March 16, 2024.	CI

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Announces 2023 Final Profit Distribution of A Shares, Payable on 09 July 2024

July 03, 2024 at 03:34 pm EDT

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. announced 2023 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 0.50000000. Record date: 08 July 2024, Ex-date: 09 July 2024 and Payment date: 09 July 2024.

Latest news about Hubei Hongyuan Pharmaceutical Technology Co., Ltd.

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Announces 2023 Final Profit Distribution of A Shares, Payable on 09 July 2024	Jul. 03	CI
Tranche Update on Hubei Hongyuan Pharmaceutical Technology Co., Ltd.'s Equity Buyback Plan announced on March 16, 2024.	Jul. 03	CI
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Approves Cash Dividend for the Year 2023	May. 15	CI
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 22	CI
Tranche Update on Hubei Hongyuan Pharmaceutical Technology Co., Ltd.'s Equity Buyback Plan announced on March 16, 2024.	Apr. 01	CI
Certain A Shares of Hubei Hongyuan Pharmaceutical Technology Co., Ltd. are subject to a Lock-Up Agreement Ending on 20-MAR-2024.	Mar. 19	CI
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. announces an Equity Buyback for CNY 99.2 million worth of its shares.	Mar. 15	CI
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. authorizes a Buyback Plan.	Mar. 12	CI
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Hubei Hongyuan Pharmaceutical Technology Co., Ltd.(XSEC:301246) added to S&P Global BMI Index	23-09-18	CI
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Announces 2022 Final Profit Distribution of A Shares, Payable on 06 June 2023	23-05-31	CI
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI

Chart Hubei Hongyuan Pharmaceutical Technology Co., Ltd.

Duration

Period

Chart Hubei Hongyuan Pharmaceutical Technology Co., Ltd.

More charts

Company Profile

Hubei Hongyuan Pharmaceutical Technology Co Ltd is a China-based company mainly engaged in the research and development, production and sales of organic chemical raw materials, pharmaceutical intermediates, raw materials and pharmaceutical preparations. The Company is also engaged in the production of lithium hexafluorophosphate, one of the main materials for lithium battery electrolyte. The Company's main products are divided into organic chemical raw materials such as glyoxal in the ethylene glycol reaction chain, pharmaceutical intermediates such as glyoxylic acid, 2-methyl-5-nitroimidazole and other products, and raw materials such as metronidazole; Pharmaceutical intermediates guanine, diacetylguanine and other products in the reaction chain of methyl cyanoacetate and guanidine hydrochloride. The Company distributes its products in the domestic market and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-29 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HUBEI HONGYUAN PHARMACEUTICAL TECHNOLOGY CO., LTD.	-48.08%	744M
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+40.42%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
ROCHE HOLDING AG	+4.21%	230B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B